In a report published Monday, Bank of America analyst Robert M. Willoughby reiterated a Buy rating on Cardinal Health CAH, and raised the price target from $86.00 to $90.00.
In the report, Bank of America noted, “Returns from its Red Oak generic sourcing JV should be evident in an improving gross profit margin over the course of 2015, and it should see added benefits from continued generic drug inflation. At 9.2x CY15 EV/EBITDA, we believe valuation remains attractive relative to AmerisourceBergen and McKesson (10.2x and 11.0x, respectively), despite the highest dividend yield in the subsector.”
Cardinal Health closed on Friday at $81.84.
Market News and Data brought to you by Benzinga APIs© 2024 Benzinga.com. Benzinga does not provide investment advice. All rights reserved.
Comments
Loading...
date | ticker | name | Price Target | Upside/Downside | Recommendation | Firm |
---|
Benzinga simplifies the market for smarter investing
Trade confidently with insights and alerts from analyst ratings, free reports and breaking news that affects the stocks you care about.
Join Now: Free!
Already a member?Sign in